The share
Stock Exchange listing
XVIVO Perfusion is listed on Nasdaq Stockholm mid cap list. The share has been listed on Nasdaq Stockholm mid cap since November 28, 2016. The XVIVO Perfusion share was before that listed on Nasdaq First North since October 8, 2012.
ISIN-code: SE0004840718
Ticker: XVIVO
Trading lot: 1 share
Shareholders
According to Euroclear Sweden’s official share register as of June 30, 2018, the total number of shareholders were 5 113. The top 10 largest shareholders held approximately 49.9 percent of the shares.
| Shareholder | Shares | % |
|---|---|---|
| Bure, AB Equity | 4 291 4832 | 16.3% |
| Swedbank ROBUR ny teknik BTI | 1 630 000 | 6.2% |
| Eccenovo AB | 1 500 000 | 5.7% |
| SEB S.A. Client Assets UCITS. | 1 256 313 | 4.8% |
| Fjärde AP-fonden | 1 100 000 | 4.2% |
| Thomas Olausson | 1 050 000 | 4.0% |
| Catella Småbolagsfond | 641 568 | 2.4% |
| Handelsbanken Liv | 636 735 | 2.4% |
| Tredje AP-fonden | 541 408 | 2.1% |
| Nordnet Pensionsförsäkring AB | 517 887 | 2.0% |
| Top 10 largest shareholders, total | 13 165 394 | 49.9% |
| Other shareholders | 13 237 102 | 50.1% |
| Total | 26 402 496 | 100% |
2012 – Allotment of acquisition cost XVIVO Perfusion decided by the Swedish Tax Agency.
In connection with Vitrolife’s distribution of the shares in Xvivo Perfusion AB, the Swedish Tax Agency has decided that 77% of the acquisition cost should be allotted to Vitrolife AB and 23% to Xvivo Perfusion AB.
Further information can be found on the Swedish Tax Agency’s website www.skatteverket.se or by using the links below:
Skatteverkets allmanna rad (SKV A 2012-28)
Skatteverkets meddelande (SKV M 2012-25)
2016 – The Swedish Tax Agency decided how to tax the Vivoline shares purchased by XVIVO Perfusion.
In connection with XVIVO Perfusion´s acquisition of Vivoline Medical AB the Swedish Tax Agency decided the tax treatment for the Vivoline shares purchased by XVIVO Perfusion AB.
Further information can be found on the Swedish Tax Agency’s website www.skatteverket.se or by using the links below:
Skatteverkets Brevsvar ang. XVIVOs köp av Aktier och Optioner i Vivoline
